Download PDF
Thromb Haemost 1998; 80(01): 74-81
DOI: 10.1055/s-0037-1615142
Rapid Communication
Schattauer GmbH

Factor XII Does not Initiate Prekallikrein Activation on Endothelial Cells

Rasmus Røjkjær
1   Department of Medical Biochemistry and Genetics, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
,
Ahmed A. K. Hasan
2   Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
,
Guacyara Motta
3   Department of Biochemistry, Escola Paulista de Medicina (UNIFESP), Sao Paulo, Brazil
,
Inger Schousboe
1   Department of Medical Biochemistry and Genetics, The Panum Institute, University of Copenhagen, Copenhagen, Denmark
,
Alvin H. Schmaier
2   Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
› Author Affiliations
Further Information

Publication History

Received 13 August 1997

Accepted after resubmission 31 March 1998

Publication Date:
08 December 2017 (online)

    Permissions and Reprints

Summary

It is well known that on artificial surfaces, binding and autoactivation of factor XII (FXII) is the initiating event of plasma prekallikrein (PK) activation. We performed investigations to examine whether this mechanism was true for FXII activation on endothelial cells (HUVEC). Activation of PK on HUVEC required an optimal substrate and Zn2+ concentration, the latter of which varied with the buffer’s carrier protein. Maximal PK activation required the addition of 250 μM or 10 μM Zn2+ to buffers containing bovine serum albumin (BSA) or gelatin, respectively. However, the actual free Zn2+ concentration in these buffers was the same at 8 μM. In both BSA- and gelatin-containing buffers and using two different chromogenic substrates for FXII, no autoactivation of FXII on HUVEC was seen when incubated for up to 60 min. Rather, initiation of FXII enzymatic activity required the presence of PK. FXII activation after PK activation contributed to the extent of measured enzymatic activity, but its role was secondary because treatment with corn trypsin inhibitor or a neutralizing antibody to FXIIa did not abolish the measured enzymatic activity. They also reduced the activity to the level seen with PK activation alone. Alternatively, soybean trypsin inhibitor abolished the proteolytic activity associated with PK and FXII activation on HUVEC. Further, only normal human and FXII-deficient plasmas, not PK-deficient plasma, had the ability to generate proteolytic activity when incubated over endothelial cells. In a purified system, maximal PK activation was measured after a 10-15 min incubation depending upon the concentration of reactants. When FXII was added with the PK, maximal activation occurred within 7.5-10 min. In normal human or FXII-deficient plasmas, but not in PK-deficient plasma, maximal activation was seen in 4 min. These data indicate that on HUVEC, unlike artificial surfaces, PK activation when bound to HK is the initiating activation event in this system. FXII activation is secondary to PK activation and contributes to the extent of measured enzymatic activity. These data challenge the accepted dogmas of “contact activation” and suggest that on biologic membranes a new notion as to how this system is activated needs to be considered.

 

  • References

  • 1 Wiggins RC, Cochrane CG. The autoactivation of rabbit Hageman factor. J Exp Med 1979; 150: 1122-33.
    CrossrefPubMedGoogle Scholar
  • 2 Miller G, Silverberg M, Kaplan AP. Autoactivability of human Hageman factor. Biochem Biophys Res Commun 1980; 92: 803-10.
    CrossrefPubMedGoogle Scholar
  • 3 Silverberg M, Dunn JT, Garen L, Kaplan AP. Autoactivation of human Hageman factor: demonstration utilizing a synthetic substrate. J Biol Chem 1980; 255: 7281-6.
    PubMedGoogle Scholar
  • 4 Schmaier AH, Farber A, Schein R, Sprung C. Structural changes of plasma high molecular weight kininogen after in vitro activation and in sepsis. J Lab Clin Med 1988; 112: 182-92.
    PubMedGoogle Scholar
  • 5 Kozin F, Cochrane CG. The contact activation system of plasma: Biochemistry and pathophysiology. In: Inflammation: Basic principles and clinical correlates. Gallin JI, Goldstein IM, Snyderman R. eds. New York: Raven Press; Ltd.: 1988. pp 101-120.
    Google Scholar
  • 6 Gurewich V, Johnstone M, Loza J-P, Pannell R. Pro-urokinase and prekallikrein are both associated with platelets. Implications for the intrinsic pathway of fibrinolysis and for therapeutic thrombolysis. FEBS Lett 1993; 318: 317-21.
    CrossrefPubMedGoogle Scholar
  • 7 Loza J-P, Gurewich V, Johnstone M, Pannell R. Platelet-bound prekallikrein promotes pro-urokinase-induced clot lysis: a mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis. Thromb Haemost 1994; 71: 347-52.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Lenich C, Pannell R, Gurewich V. Assembly and activation of the intrinsic fibrinolytic pathway on the surface of human endothelial cells in culture. Thromb Haemost 1995; 74: 698-703.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Shimada T, Kato H, Iwanaga S. Accelerating effect of zinc ions on the surface-mediated activation of factor XII and prekallikrein. J Biochem (Tokyo) 1987; 102: 913-21.
    CrossrefPubMedGoogle Scholar
  • 10 Shore JD, Day DE, Bock PE, Olson ST. Acceleration of surface dependent autocatalytic activation of blood coagulation factor XII by divalent metal ions. Biochemistry 1987; 26: 2250-8.
    CrossrefPubMedGoogle Scholar
  • 11 Schousboe I. The inositol-phospholipid-accelerated activation of prekallikrein by activated factor XII at physiological ionic strength requires zinc ions and high-Mr kininogen. Eur J Biochem 1990; 193: 495-9.
    CrossrefPubMedGoogle Scholar
  • 12 Røjkjær R, Schousboe I. The surface dependent autoactivation mechanism of factor XII. Eur J Biochem 1997; 243: 160-6.
    CrossrefPubMedGoogle Scholar
  • 13 Bernardo MM, Day DE, Olson ST, Shore JD. Surface-independent acceleration of factor XII activation by zinc ions. I. Kinetic characterization of the metal ion rate enhancement. J Biol Chem 1993; 268: 12468-76.
    PubMedGoogle Scholar
  • 14 Bernardo MM, Day DE, Halvorson HR, Olson ST, Shore JD. Surface-independent acceleration of factor XII activation by zinc ions. II. Direct binding and fluorescence studies. J Biol Chem 1993; 268: 12477-83.
    PubMedGoogle Scholar
  • 15 Røjkjær R, Schousboe I. Partial identification of the Zn2+-binding sites in factor XII and its derivatives. Eur J Biochem 1997; 247: 491-6.
    CrossrefPubMedGoogle Scholar
  • 16 Schmaier AH, Kuo A, Lundberg D, Murray S, Cines DB. Expression of high molecular weight kininogen on human umbilical vein endothelial cells. J Biol Chem 1988; 263: 16327-33.
    PubMedGoogle Scholar
  • 17 Meloni FJ, Schmaier AH. Low molecular weight kininogen binds to platelets to modulate thrombin-induced platelet activation. J Biol Chem 1991; 266: 6786-94.
    PubMedGoogle Scholar
  • 18 Gustafson EG, Schmaier AH, Wachtfogel YT, Kaufman N, Kucich U, Colman RW. Human neutrophils contain and bind high molecular weight kininogen. J Clin Invest 1989; 84: 28-35.
    CrossrefPubMedGoogle Scholar
  • 19 Reddigari SR, Shibayama T, Brunnee T, Kaplan AP. Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. J Biol Chem 1993; 268: 11982-7.
    PubMedGoogle Scholar
  • 20 Motta G, Røjkjær R, Hasan AAK, Cines DB, Schmaier AH. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: A novel mechanism for contact activation . Blood 1998; 91: 516-28.
    PubMedGoogle Scholar
  • 21 Lin Y, Harris RB, Yan W, McCrae KR, Zhang H, Colman RW. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation. Blood 1997; 90: 690-7.
    PubMedGoogle Scholar
  • 22 Fisher CA, Schmaier AH, Addonizio VP, Colman RW. Assay of plasma prekallikrein: comparison of amidolytic, esterolytic, coagulation and immunochemical assays. Blood 1982; 59: 963-70.
    PubMedGoogle Scholar
  • 23 Hasan AAK, Cines DB, Herwald H, Schmaier AH, Müller-Esterl W. Mapping the cell binding site on high molecular weight kininogen’s domain 5. J Biol Chem 1995; 270: 19256-61.
    CrossrefPubMedGoogle Scholar
  • 24 Kaufman J, Haaseman M, Modrow S, Muller-Esterl W. Structural dissection of the multidomain kininogens. Fine mapping of the target epitopes of antibodies interfering with their functional properties. J Biol Chem 1993; 268: 9079-91.
    PubMedGoogle Scholar
  • 25 Schousboe I, Røjkjær R, Lintner R. Functional determination of factor XII in plasma. Clin Appl Thromb Hemost 1996; 2 (02) 123-9.
    CrossrefPubMedGoogle Scholar
  • 26 Johnson DA, Gautsch JW, Sportsman JR, Elder JH. Improved technique utilizing nonfat dry milk for analysis of proteins and nucleic acids transferred to nitrocellulose. Gene Anal Tech 1984; 1: 3-8.
    CrossrefPubMedGoogle Scholar
  • 27 D’Haese PC, Lamberts LV, Vanheule AO, De Broe ME. Direct determination of zinc in serum by zeeman atomic absorption spectrometry with a graphite furnace. Clin Chem 1992; 38: 2439-43.
    PubMedGoogle Scholar
  • 28 Prasad AS, Oberleas D. Binding of zinc to amino acids and serum proteins in vitro. J Lab Clin Med 1970; 36: 416-25.
    PubMedGoogle Scholar
  • 29 Ratnoff OD, Evarson B, Embyry P, Ziats NP, Anderson JM, Emanuelson MM, Malemud CJ. Inhibition of the activation of Hageman factor (factor XII) by human vascular endothelial cell culture supernatates. Proc Natl Acad Sci 1991; 88: 10740-3.
    CrossrefPubMedGoogle Scholar
  • 30 Kleniewski J, Donaldson VH. Endothelial cells produce a substance that inhibits contact activation of coagulation by blocking the activation of Hageman factor. Proc Natl Acad Sci 1993; 90: 198-202.
    CrossrefPubMedGoogle Scholar
  • 31 Ratnoff OD, Emanuelson MM, Ziats NP. Inhibition of the activation of Hageman factor (factor XII) by peripheral blood cells. J Clin Invest 1987; 80: 1180-9.
    CrossrefPubMedGoogle Scholar
  • 32 Ratnoff OD, Gleich GJ, Shurin SB, Kazura J, Everson B, Embury P. Inhibition of the activation of hageman factor (Factor XII) by eosinophils and eosinophilic constituents. Am L Hematol 1993; 42: 138-45.
    PubMedGoogle Scholar
  • 33 Woo J, Cannon DC. In: Clinical Diagnosis and Management Laboratory Methods. Henry II JB. ed. Philadelphia: Saunders; 1984. 17ed Ed, pp 16-162.
    Google Scholar
  • 34 Whitehouse RC, Prasad AS, Rabbani PI, Cossack ZT. Zinc in plasma, neutrophils, lymphocytes and erythrocytes as determined by flameless atomic absorbtion spectrophotometry. Clin Chem 1982; 28: 475-80.
    PubMedGoogle Scholar
  • 35 Whitehouse RC, Prasad AS, Cossack ZT. Determination of ultrafiltrable zinc in plasma by flameless atomic absorption spectrophotometry. Clin Chem 1983; 29: 1971-7.
    PubMedGoogle Scholar
  • 36 Cunningham BC, Bass S, Fuh G, Wells JA. Zinc mediation of the binding of human growth hormone to the human prolactin receptor. Science 1990; 250: 1709-12.
    CrossrefPubMedGoogle Scholar
  • 37 Foley B, Johnson SA, Hackley B, Smith Jr JC, Halsted JA. Zinc content of human platelets. Proc Soc Exp Biol Med 1968; 128: 266-9.
    PubMedGoogle Scholar
  • 38 Baker RJ, McNeil JJ, Lander H. Platelet metal levels in normal subjects determined by atomic absorption spectrophotometry. Thromb Haemost 1978; 39: 360-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 Kiem J, Borberg H, Iyengar GV, Kasperek K, Siegers M, Feinendegen LE, Gross R. Elemental composition of platelets. Part II: Water content of normal human platelets and measurements of their concentration of Cu, Fe, K, and Zn by neutron activation analysis. Clin Chem 1979; 25: 705-10.
    PubMedGoogle Scholar
  • 40 Aktulga A, Ulutin ON. Normal human platelet zinc content and its release. In: Monograph: Platelets. Ulutin ON. ed. Amsterdam: Excerpta Medica; 1975
    Google Scholar